Brain cholinergic imaging in isolated REM sleep behavior disorder: Distinctions and similarities with Parkinson's disease.
Brain cholinergic imaging in isolated REM sleep behavior disorder: Distinctions and similarities with Parkinson's disease.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Québec, CA · Author affiliation
NeuroQAM, Université du Québec à Montréal (UQAM), 100 Sherbrooke St West, Montréal, QC, H2X 3P2, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, 3801 University Street, Montréal, QC, H3A 2B4, Canada.Location evidence
Montréal, CA · Author affiliation
NeuroQAM, Université du Québec à Montréal (UQAM), 100 Sherbrooke St West, Montréal, QC, H2X 3P2, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, 3801 University Street, Montréal, QC, H3A 2B4, Canada.Location evidence
Sherbrooke, CA · Author affiliation
NeuroQAM, Université du Québec à Montréal (UQAM), 100 Sherbrooke St West, Montréal, QC, H2X 3P2, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, 3801 University Street, Montréal, QC, H3A 2B4, Canada.Location evidence
LaSalle, CA · Author affiliation
NeuroQAM, Université du Québec à Montréal (UQAM), 100 Sherbrooke St West, Montréal, QC, H2X 3P2, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institute, 3801 University Street, Montréal, QC, H3A 2B4, Canada; McGill Centre for Studies in Aging, Douglas Mental Health University Institute, 6825 LaSalle Boulevard, Montréal, QC, H4H 1R3, Canada; Department of Neurology and Neurosurgery, McGill University, 3801 University Street, Montréal, QC, H3A 2B4, Canada. Electronic address: bedard.marc-andre@uqam.ca.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of α-synucleinopathy such as Parkinson's disease (PD). Brain cholinergic alterations have been reported in these diseases, but direct comparisons of terminal density between iRBD and clinically manifest PD have not yet been performed. OBJECTIVES: To assess brain cholinergic terminal density in iRBD using positron emission tomography (PET) with [18F]-fluoroethoxybenzovesamicol (FEOBV), and to compare findings with both healthy controls and patients with PD. METHODS: Forty-six participants (16 with polysomnography-confirmed iRBD, 12 with PD, and 18 controls) underwent high-resolution PET neuroimaging with FEOBV. Voxel-wise analyses and effect size mapping were conducted to compare the groups, using standardized uptake value ratios (SUVRs). Correlations were performed between whole-cortex SUVR and clinical measures. RESULTS: Compared to controls, both the iRBD and PD groups exhibited significant cortical cholinergic denervation of similar magnitudes (11-12 %). Effect size mapping revealed very large losses (Cohen's ds < -1.5) in the posterior cortex in both patient groups, predominantly occipital-parietal in iRBD and occipital-temporal in PD. In iRBD, lower cortical uptake was associated with poorer performance on executive and visuospatial tests. Moreover, in iRBD but not in PD, there was a trend toward higher FEOBV uptake in subcortical areas, including brainstem regions. CONCLUSIONS: Cholinergic denervation in iRBD is comparable in extent to that in PD, with subtle topographic distinctions, and correlates with cognitive deficits.